Linked Life Data

21156403

Source:http://linkedlifedata.com/resource/pubmed/id/21156403

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2010-12-15
pubmed:abstractText
Resistance to cisplatin in the course of chemotherapy contributes to the poor prognosis of small cell lung cancer (SCLC). B cell lymphoma-2 is the founding member of a large family of proteins that either promote or inhibit apoptosis. We aimed at investigating if the pro-apoptotic members Bad, Bax, Bim and Bid are involved in cisplatin-resistance. - Cisplatin-resistance in the SCLC cell line H1339 was induced by repetitive exposure to cisplatin. Protein expression was quantified by Western Blot and immuno-fluorescence analysis. Protein expression was altered using siRNA interference. - Four cycles of 0.5 ?g/ml cisplatin led to partial cisplatin-resistance in H1339 cells. The expression of Bad, Bim and Bid was comparable in naive and resistant cells while the expression of Bax was reduced in the resistant clone. But, reducing Bax expression in naive cells did not lead to altered cisplatin sensitivity neither in H1339 nor in H187 SCLC cells. - We conclude that the reduced Bax expression after exposure to cisplatin is not sufficient to induce cisplatin-resistance in SCLC cells.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0949-2321
pubmed:author
pubmed:issnType
Print
pubmed:day
25
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
448-51
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Reduced expression of Bax in small cell lung cancer cells is not sufficient to induce cisplatin-resistance.
pubmed:affiliation
Department of Pulmonary Medicine, Medizinsche Klinik-Innenstadt, Ludwi-Maximilians-University, Munich, Germany.
pubmed:publicationType
Journal Article